Lv32
354 积分 2021-02-07 加入
Combining ctDNA and utDNA as a Dual Biomarker-driven Strategy for Bladder-sparing Therapy in Muscle-invasive Bladder Cancer: Neither Alone Is Sufficient
5小时前
求助中
Letter to the Editor: Advanced and Metastatic Prostate Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment, and Follow-up
4天前
求助中
IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer
4天前
已完结
Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium
6天前
已关闭
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
8天前
已完结
HER2 in urothelial cancer: clinical speed outpacing diagnostic clarity
10天前
已完结
Two decades of PARP inhibitor synthetic lethality in cancer
10天前
已完结
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma
13天前
已完结
Listening to the bladder field: Urine liquid biopsies reveal differential treatment responses in NMIBC
19天前
已完结
Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally
21天前
已完结
皖公网安备34019202002308
